A sterilised male mosquito is prepared to be released from quarantine. PHOTO: EPA
SINGAPORE: Singapore patients will play a key role in testing a new dengue vaccine, one which pharmaceutical giant Takeda hopes will put the brakes on the mosquito-borne disease which is endemic here and in many other countries worldwide.
The Japanese firm is conducting a trial of its vaccine at two public hospitals here, and is recruiting 400 people - both those who have and have not been infected. So far, at least 300 participants have signed up.
